Breaking News Instant updates and real-time market news.

QTRHF

Quarterhill

$1.21 /

+ (+0.00%)

06:39
10/05/20
10/05
06:39
10/05/20
06:39

Quarterhill subsidiary awarded $1.2M WIM systems contract from FHWA

International Road Dynamics, or IRD, a Quarterhill company, announced that it has been awarded a contract for "Weigh-In-Motion Systems Installation, Maintenance, and Data Services" with the United States Federal Highway Administration, or FHWA, Office of Infrastructure Research and Development, which is part of the U.S. Department of Transportation. The contract is a task-order based, indefinite-delivery-indefinite-quantity, agreement covering a 66-month period and is valued at $1.2M. Under this contract, IRD will be issued task orders to provide installation, maintenance, repairs and verification that data collected from the WIM systems at long-term pavement performance, or LTPP, test sites across the United States and Canada meet performance specifications for Type I WIM systems established by American Society for Testing and Materials, or ASTM, Standard E1318-09. The FHWA funds and manages the LTPP program with the goal of investigating specific pavement-related details that are critical to pavement performance. LTPP program studies are performed at more than 2,500 test sections on highways across North America.

QTRHF Quarterhill
$1.21 /

+ (+0.00%)

08/10/20 CIBC
Quarterhill price target raised to C$4 from C$3.47 at CIBC

TODAY'S FREE FLY STORIES

Hot Stocks
Cricut holder Abdiel Capital buys 268.7K shares of common stock » 20:30
09/22/21
09/22
20:30
09/22/21
20:30
CRCT

Cricut

$31.02 /

-0.44 (-1.40%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRCT Cricut
$31.02 /

-0.44 (-1.40%)

CRCT Cricut
$31.02 /

-0.44 (-1.40%)

08/17/21 Barclays
Cricut downgraded to Equal Weight from Overweight at Barclays
08/13/21
Fly Intel: Top five analyst downgrades
08/13/21 Goldman Sachs
Cricut downgraded to Neutral from Buy at Goldman Sachs
08/13/21 Morgan Stanley
Cricut downgraded to Underweight from Equal Weight at Morgan Stanley
CRCT Cricut
$31.02 /

-0.44 (-1.40%)

  • 25
    Mar
CRCT Cricut
$31.02 /

-0.44 (-1.40%)

CRCT Cricut
$31.02 /

-0.44 (-1.40%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
09/22/21
09/22
20:25
09/22/21
20:25
DRI

Darden

$150.35 /

+3.72 (+2.54%)

, RAD

Rite Aid

$15.25 /

+0.18 (+1.19%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Darden Restaurants (DRI), consensus $1.63... Rite Aid (RAD), consensus (42c).

ShowHide Related Items >><<
DRI Darden
$150.35 /

+3.72 (+2.54%)

RAD Rite Aid
$15.25 /

+0.18 (+1.19%)

DRI Darden
$150.35 /

+3.72 (+2.54%)

09/15/21 RBC Capital
RBC Capital estimating in-line Q1 earnings for Darden
08/09/21
Fly Intel: Top five analyst downgrades
08/09/21 Evercore ISI
Darden downgraded to In Line from Outperform at Evercore ISI
08/09/21 Evercore ISI
Darden downgraded to In Line from Outperform at Evercore ISI
RAD Rite Aid
$15.25 /

+0.18 (+1.19%)

06/25/21
Fly Intel: Top five analyst downgrades
06/25/21 JPMorgan
Rite Aid downgraded to Underweight from Neutral at JPMorgan
06/25/21 Deutsche Bank
Rite Aid price target lowered to $13 from $18 at Deutsche Bank
06/22/21 Deutsche Bank
Rite Aid price target lowered to $18 from $27 at Deutsche Bank
DRI Darden
$150.35 /

+3.72 (+2.54%)

RAD Rite Aid
$15.25 /

+0.18 (+1.19%)

DRI Darden
$150.35 /

+3.72 (+2.54%)

RAD Rite Aid
$15.25 /

+0.18 (+1.19%)

DRI Darden
$150.35 /

+3.72 (+2.54%)

RAD Rite Aid
$15.25 /

+0.18 (+1.19%)

DRI Darden
$150.35 /

+3.72 (+2.54%)

RAD Rite Aid
$15.25 /

+0.18 (+1.19%)

Syndicate
Grinrod Shipping 1.842M share Spot Secondary priced at $13.50 » 20:20
09/22/21
09/22
20:20
09/22/21
20:20
GRIN

Grinrod Shipping

$15.57 /

-0.92 (-5.58%)

The deal priced at low…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GRIN Grinrod Shipping
$15.57 /

-0.92 (-5.58%)

  • 23
    Sep
Syndicate
Safehold 2.2M share Secondary priced at $76.00 » 20:18
09/22/21
09/22
20:18
09/22/21
20:18
SAFE

Safehold

$76.42 /

-3.56 (-4.45%)

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAFE Safehold
$76.42 /

-3.56 (-4.45%)

SAFE Safehold
$76.42 /

-3.56 (-4.45%)

09/21/21
Safehold files to sell 2M shares and concurrent private placement
07/30/21 Truist
Safehold price target raised to $80 from $72 at Truist
07/27/21 B. Riley
Safehold price target raised to $110 from $100 at B. Riley
07/22/21 Truist
Truist 'not overly concerned' by Safehold earnings miss
SAFE Safehold
$76.42 /

-3.56 (-4.45%)

  • 23
    Sep
  • 11
    Nov
SAFE Safehold
$76.42 /

-3.56 (-4.45%)

Hot Stocks
Aerojet Rocketdyne conducts 'solid rocket motor test firing' at Arkansas site » 19:42
09/22/21
09/22
19:42
09/22/21
19:42
AJRD

Aerojet Rocketdyne

$41.32 /

-0.665 (-1.58%)

Aerojet Rocketdyne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

04/27/21 Truist
Aerojet Rocketdyne price target lowered to $51 from $56 at Truist
01/07/21 Jefferies
Jefferies downgrades Aerojet Rocketdyne to Hold, sees higher bid as unlikely
01/07/21 Jefferies
Aerojet Rocketdyne downgraded to Hold from Buy at Jefferies
12/22/20 Credit Suisse
Lockheed Martin price target raised to $409 from $400 at Credit Suisse
AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

AJRD Aerojet Rocketdyne
$41.32 /

-0.665 (-1.58%)

Hot Stocks
Buenaventura announces strike at Uchucchacua Mine » 19:38
09/22/21
09/22
19:38
09/22/21
19:38
BVN

Buenaventura

$7.53 /

+0.17 (+2.31%)

Compania de Minas…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BVN Buenaventura
$7.53 /

+0.17 (+2.31%)

03/08/21 Citi
Buenaventura price target lowered to $12 from $13 at Citi
12/15/20 Goldman Sachs
Buenaventura downgraded to Neutral from Buy at Goldman Sachs
Syndicate
Brilliant Earth 8.33M share IPO priced at $12.00 » 19:25
09/22/21
09/22
19:25
09/22/21
19:25
BRLT

Brilliant Earth

/

+

The deal size was reduced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 23
    Sep
Conference/Events
Yum China to hold virtual investor day » 19:25
09/22/21
09/22
19:25
09/22/21
19:25
YUMC

Yum China

$54.43 /

+0.3 (+0.55%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

09/20/21 Stifel
Starbucks price target trimmed to $130 at Stifel after Yum China disclosures
09/15/21 Macquarie
Macquarie downgrades Yum China to sell on 'bumpy' sales recovery
09/15/21 Macquarie
Yum China downgraded to Underperform from Neutral at Macquarie
07/07/21 Goldman Sachs
Yum China price target raised to $77 from $74 at Goldman Sachs
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

Hot Stocks
Ingredion raises quarterly dividend to 65c per share from 64c » 19:22
09/22/21
09/22
19:22
09/22/21
19:22
INGR

Ingredion

$87.47 /

+0.305 (+0.35%)

The dividend is payable…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INGR Ingredion
$87.47 /

+0.305 (+0.35%)

INGR Ingredion
$87.47 /

+0.305 (+0.35%)

09/10/21 Lake Street
S&W Seed pact with Ingredion a 'potential needle-mover,' says Lake Street
05/05/21 Stephens
Stephens downgrades Ingredion to Equal Weight on lower beat and raise potential
05/05/21 Stephens
Ingredion downgraded to Equal Weight from Overweight at Stephens
INGR Ingredion
$87.47 /

+0.305 (+0.35%)

INGR Ingredion
$87.47 /

+0.305 (+0.35%)

Syndicate
Sovos Brands 23.3M share IPO priced at $12.00 » 19:21
09/22/21
09/22
19:21
09/22/21
19:21
SOVO

Sovos Brands

/

+

The deal priced below the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 23
    Sep
Syndicate
Sterling Check 14.285M share IPO priced at $23.00 » 19:10
09/22/21
09/22
19:10
09/22/21
19:10
STER

Sterling Check

/

+

The deal priced above the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
  • 23
    Sep
Hot Stocks
Amazon Web Services to open data centers in New Zealand » 18:53
09/22/21
09/22
18:53
09/22/21
18:53
AMZN

Amazon.com

$3,380.08 /

+33.19 (+0.99%)

Amazon Web Services…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

09/14/21 Evercore ISI
Amazon price target raised to $4,700 from $4,200 at Evercore ISI
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Amazon.com initiated with a Buy at Goldman Sachs
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

Hot Stocks
TScan Therapeutics director buys 5K shares of common stock » 18:52
09/22/21
09/22
18:52
09/22/21
18:52
TCRX

TScan Therapeutics

$6.19 /

-0.23 (-3.58%)

In a regulatory filing,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

08/13/21 Cowen
Cowen sees upside for TScan Therapeutics, starts with Outperform
08/13/21 Cowen
TScan Therapeutics initiated with an Outperform at Cowen
08/10/21 Jefferies
TScan Therapeutics initiated with a Buy at Jefferies
08/10/21 Morgan Stanley
TScan Therapeutics initiated with an Overweight at Morgan Stanley
TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

  • 16
    Jul
TCRX TScan Therapeutics
$6.19 /

-0.23 (-3.58%)

Hot Stocks
Amplitude Healthcare Acquisition Corp stockholders approve Jasper combination » 18:42
09/22/21
09/22
18:42
09/22/21
18:42
AMHC

Amplitude Healthcare Acquisition Corp

$10.22 /

-0.28 (-2.67%)

Amplitude Healthcare…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AMHC Amplitude Healthcare Acquisition Corp
$10.22 /

-0.28 (-2.67%)

Syndicate
Inotiv prices upsized $125M convertible senior note offering » 18:39
09/22/21
09/22
18:39
09/22/21
18:39
NOTV

Inotiv

$34.21 /

-15.715 (-31.48%)

The initial conversion…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

08:43 Today Craig-Hallum
Inotiv price target raised to $57 from $45 at Craig-Hallum
09/20/21 Craig-Hallum
Craig-Hallum bullish on Inotiv, initiates with a Buy
09/20/21 Craig-Hallum
Inotiv initiated with a Buy at Craig-Hallum
NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

  • 21
    Apr
NOTV Inotiv
$34.21 /

-15.715 (-31.48%)

Recommendations
Gazprom price target raised to $12 from $10.50 at Goldman Sachs » 18:33
09/22/21
09/22
18:33
09/22/21
18:33
OGZPY

Gazprom

$9.29 /

+0.13 (+1.42%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
OGZPY Gazprom
$9.29 /

+0.13 (+1.42%)

06/25/21 UBS
Gazprom upgraded to Buy on higher gas prices at UBS
06/25/21 UBS
Gazprom upgraded to Buy from Neutral at UBS
06/10/21 Erste Group
Gazprom upgraded to Hold from Sell at Erste Group
12/23/20 JPMorgan
Gazprom upgraded to Overweight from Neutral at JPMorgan
Upgrade
Lukoil upgraded to Buy from Neutral at Goldman Sachs » 18:30
09/22/21
09/22
18:30
09/22/21
18:30
LUKOY

Lukoil

$92.00 /

+1.49 (+1.65%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LUKOY Lukoil
$92.00 /

+1.49 (+1.65%)

07/07/21 Renaissance Capital
Lukoil downgraded to Hold from Buy at Renaissance Capital
02/09/21 VTB Capital
Lukoil upgraded to Buy from Hold at VTB Capital
11/27/20 VTB Capital
Lukoil downgraded to Hold from Buy at VTB Capital
Hot Stocks
Unity Software CEO: At our core we are SAS company » 18:24
09/22/21
09/22
18:24
09/22/21
18:24
U

Unity Software

$133.51 /

+2.49 (+1.90%)

In an interview on…

In an interview on CNBC's Mad Money, John Riccitiello said Unity provides technology for anything that is real-time 3D. The metaverse is the internet 3.0, he noted. The company has been growing at a 40% rate for the past few quarters he added.

ShowHide Related Items >><<
U Unity Software
$133.51 /

+2.49 (+1.90%)

U Unity Software
$133.51 /

+2.49 (+1.90%)

09/10/21 Wedbush
Wedbush says Apple injunction could boost earnings for mobile game makers
08/31/21 Macquarie
Macquarie starts 'one-of-a-kind' Unity Software at Outperform
08/31/21 Macquarie
Unity Software initiated with an Outperform at Macquarie
08/11/21 Goldman Sachs
Unity Software initiated with a Buy at Goldman Sachs
U Unity Software
$133.51 /

+2.49 (+1.90%)

  • 08
    Feb
U Unity Software
$133.51 /

+2.49 (+1.90%)

U Unity Software
$133.51 /

+2.49 (+1.90%)

U Unity Software
$133.51 /

+2.49 (+1.90%)

On The Fly
Fly Intel: After-Hours Movers » 18:23
09/22/21
09/22
18:23
09/22/21
18:23
BB

BlackBerry

$9.56 /

+0.185 (+1.97%)

, FUL

H.B. Fuller

$60.44 /

+0.55 (+0.92%)

, MRM

Medirom Healthcare

$7.40 /

+0.15 (+2.07%)

, HRMY

Harmony Biosciences

$37.49 /

-1.09 (-2.83%)

, AVDL

Avadel Pharmaceuticals

$8.19 /

+0.065 (+0.80%)

, SAGE

Sage Therapeutics

$44.31 /

-0.895 (-1.98%)

, ARD

Ardagh Group

$24.65 /

+0.7 (+2.92%)

, JAZZ

Jazz Pharmaceuticals

$129.60 /

+0.36 (+0.28%)

, EAR

Eargo

$21.68 /

-0.39 (-1.77%)

, SYBX

Synlogic

$3.52 /

-0.04 (-1.12%)

, SCS

Steelcase

$13.35 /

+0.23 (+1.75%)

, REXR

Rexford Industrial

$60.18 /

+0.02 (+0.03%)

, KBH

KB Home

$40.95 /

+0.285 (+0.70%)

Check out this evening's…

ShowHide Related Items >><<
SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

REXR Rexford Industrial
$60.18 /

+0.02 (+0.03%)

MRM Medirom Healthcare
$7.40 /

+0.15 (+2.07%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

HRMY Harmony Biosciences
$37.49 /

-1.09 (-2.83%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

EAR Eargo
$21.68 /

-0.39 (-1.77%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

AVDL Avadel Pharmaceuticals
$8.19 /

+0.065 (+0.80%)

ARD Ardagh Group
$24.65 /

+0.7 (+2.92%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Canaccord
BlackBerry upgraded to Hold from Sell at Canaccord
06/25/21
Fly Intel: Top five analyst downgrades
06/25/21 TD Securities
BlackBerry downgraded to Reduce from Hold at TD Securities
FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

08/31/21 Citi
MasTec added to 'Value Creators' list at Citi, H.B. Fuller removed
06/25/21 Deutsche Bank
H.B. Fuller price target raised to $67 from $65 at Deutsche Bank
06/25/21 Citi
H.B. Fuller downgraded to Neutral from Buy at Citi
MRM Medirom Healthcare
$7.40 /

+0.15 (+2.07%)

HRMY Harmony Biosciences
$37.49 /

-1.09 (-2.83%)

16:22 Today Needham
Harmony Biosciences initiated with a Buy at Needham
03/29/21 Goldman Sachs
Harmony Biosciences upgraded to Buy from Neutral at Goldman Sachs
AVDL Avadel Pharmaceuticals
$8.19 /

+0.065 (+0.80%)

16:22 Today Needham
Avadel Pharmaceuticals initiated with a Buy at Needham
08/10/21 H.C. Wainwright
Avadel Pharmaceuticals approvability concerns 'overblown,' says H.C. Wainwright
03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

16:27 Today Needham
Sage Therapeutics initiated with a Buy at Needham
08/04/21 RBC Capital
Sage Therapeutics price target lowered to $55 from $60 at RBC Capital
08/04/21 H.C. Wainwright
Sage Therapeutics price target lowered to $80 from $86 at H.C. Wainwright
07/27/21 Canaccord
Sage Therapeutics price target lowered to $96 from $119 at Canaccord
ARD Ardagh Group
$24.65 /

+0.7 (+2.92%)

09/01/21 Citi
Ardagh Group resumed with a Buy at Citi
08/26/21
Fly Intel: Top five analyst initiations
08/26/21 Deutsche Bank
Ardagh Group resumed with a Buy at Deutsche Bank
05/26/21
Fly Intel: Top five analyst downgrades
JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

16:24 Today Needham
Jazz Pharmaceuticals initiated with a Buy at Needham
07/23/21 RBC Capital
Jazz Pharmaceuticals price target raised to $216 from $190 at RBC Capital
07/15/21 JPMorgan
JPMorgan stays bullish on Jazz Pharmaceuticals after physician survey
EAR Eargo
$21.68 /

-0.39 (-1.77%)

07/12/21 William Blair
William Blair says Biden exeuctive order not 'thesis-changer' for Eargo
07/09/21 Wells Fargo
Eargo selloff on White House order unwarranted, says Wells Fargo
06/22/21 Wells Fargo
Eargo5 launch appears to be on track, says Wells Fargo
05/13/21 Wells Fargo
Eargo price target lowered to $52 from $68 at Wells Fargo
SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

09/20/21 Chardan
Synlogic phenylketonuria data 'encouraging,' says Chardan
09/20/21 Piper Sandler
Synlogic price target raised to $9 at Piper Sandler on positive SynPHEny data
07/09/21 Chardan
Synlogic assumed with a Buy at Chardan
06/28/21 H.C. Wainwright
Synlogic price target lowered to $9 from $13 at H.C. Wainwright
SCS Steelcase
$13.35 /

+0.23 (+1.75%)

05/11/21 Berenberg
Berenberg starts 'market leader' Steelcase at Buy
05/11/21 Berenberg
Steelcase initiated with a Buy at Berenberg
05/07/21 Benchmark
Benchmark upgrades Steelcase to Buy on signs of recovery in commercial furniture
05/07/21 Benchmark
Steelcase upgraded to Buy from Hold at Benchmark
REXR Rexford Industrial
$60.18 /

+0.02 (+0.03%)

08/10/21 Wells Fargo
Rexford Industrial price target raised to $65 from $58 at Wells Fargo
07/19/21 Capital One
Rexford Industrial upgraded to Overweight from Equalweight at Capital One
06/07/21 Wells Fargo
Rexford Industrial price target raised to $58 from $51 at Wells Fargo
10/28/20 Berenberg
Rexford Industrial initiated with a Buy at Berenberg
KBH KB Home
$40.95 /

+0.285 (+0.70%)

07/19/21
Fly Intel: Top five analyst upgrades
07/19/21 Seaport Global
KB Home upgraded to Buy from Neutral at Seaport Global
06/24/21 RBC Capital
KB Home price target raised to $47 from $46 at RBC Capital
06/15/21 Wedbush
Wedbush sees pullback in KB Home shares as buying opportunity
SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

REXR Rexford Industrial
$60.18 /

+0.02 (+0.03%)

MRM Medirom Healthcare
$7.40 /

+0.15 (+2.07%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

HRMY Harmony Biosciences
$37.49 /

-1.09 (-2.83%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

EAR Eargo
$21.68 /

-0.39 (-1.77%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

AVDL Avadel Pharmaceuticals
$8.19 /

+0.065 (+0.80%)

ARD Ardagh Group
$24.65 /

+0.7 (+2.92%)

  • 23
    Sep
  • 23
    Sep
  • 25
    May
  • 16
    Apr
  • 29
    Dec
  • 02
    Dec
  • 16
    Oct
KBH KB Home
$40.95 /

+0.285 (+0.70%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

SYBX Synlogic
$3.52 /

-0.04 (-1.12%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

SAGE Sage Therapeutics
$44.31 /

-0.895 (-1.98%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

JAZZ Jazz Pharmaceuticals
$129.60 /

+0.36 (+0.28%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

EAR Eargo
$21.68 /

-0.39 (-1.77%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

SCS Steelcase
$13.35 /

+0.23 (+1.75%)

KBH KB Home
$40.95 /

+0.285 (+0.70%)

FUL H.B. Fuller
$60.44 /

+0.55 (+0.92%)

BB BlackBerry
$9.56 /

+0.185 (+1.97%)

Hot Stocks
Axonics Medtronic provides update on inter partes review proceedings » 18:14
09/22/21
09/22
18:14
09/22/21
18:14
AXNX

Axonics

$69.84 /

+0.56 (+0.81%)

, MDT

Medtronic

$128.90 /

+1 (+0.78%)

Axonics (AXNX) announced…

Axonics (AXNX) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic (MDT) patents that Axonics is contesting. In March 2020, Axonics filed petitions with the PTAB requesting inter partes review to contest the validity of patents Medtronic has alleged to be infringed by Axonics. In September 2020, the PTAB granted Axonics' request and instituted a review of the six Medtronic patents. On September 13, 2021, the PTAB issued its decision with respect to Patent Nos. 7,774,069; 8,626,314, and 8,036,756. Today, the PTAB issued its decision on the three remaining Medtronic patents Axonics is contesting: Patent Nos. 9,821,112 ('112 patent), 8,457,758 ('758 patent); and 8,738,148 ('148 patent). Either party may appeal the IPR decisions to the Director of the Patent & Trademark Office and to the U.S. Court of Appeals for the Federal Circuit. Axonics expects the stay on legal proceedings in the U.S. District Court in the Central District of California to continue until the appeals process is complete. "First and foremost, it is important to understand that the PTAB rulings as to whether the claims in the Medtronic patents are valid or not do not mean that anyone has 'won' anything. When one party suggests that another party is infringing, the other party often asks the PTAB to determine if the claims in the patents are actually valid. This is what Axonics has done and for Medtronic to claim 'victory' is purely posturing. The fact that the PTAB decided to invalidate several claims in Medtronic's '112 patent is a net positive for Axonics. Moreover, we believe the PTAB's narrow construction of the claims in the '758 patent and '148 patent strengthens our non-infringement argument. Axonics remains confident that it does not infringe any Medtronic patents - valid or invalid - and that we will ultimately prevail on the patent claims asserted against us," said Raymond Cohen, CEO of Axonics.

ShowHide Related Items >><<
MDT Medtronic
$128.90 /

+1 (+0.78%)

AXNX Axonics
$69.84 /

+0.56 (+0.81%)

AXNX Axonics
$69.84 /

+0.56 (+0.81%)

08/06/21 Barclays
Axonics price target raised to $79 from $74 at Barclays
08/06/21 Piper Sandler
Axonics price target raised to $78 from $75 at Piper Sandler
07/16/21 Barclays
Axonics recall of Bulkamid is not material, says Barclays
07/12/21
Fly Intel: Top five analyst initiations
MDT Medtronic
$128.90 /

+1 (+0.78%)

09/14/21 Piper Sandler
CMS full repeal proposal of MCIT negative for med tech, says Piper Sandler
08/27/21 Argus
Medtronic price target raised to $165 from $150 at Argus
08/25/21 Truist
Medtronic price target raised to $148 from $138 at Truist
08/25/21 Credit Suisse
Medtronic price target raised to $146 from $137 at Credit Suisse
MDT Medtronic
$128.90 /

+1 (+0.78%)

AXNX Axonics
$69.84 /

+0.56 (+0.81%)

  • 12
    May
MDT Medtronic
$128.90 /

+1 (+0.78%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

MDT Medtronic
$128.90 /

+1 (+0.78%)

Periodicals
FDA set to authorize Pfizer booster shots Wednesday, Bloomberg says » 18:10
09/22/21
09/22
18:10
09/22/21
18:10
PFE

Pfizer

$43.95 /

+0.04 (+0.09%)

, BNTX

BioNTech

$339.40 /

-2.11 (-0.62%)

The FDA is slated to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

08/27/21 UBS
BioNTech price target raised to $300 from $111 at UBS
08/20/21 Canaccord
BioNTech price target raised to $450 from $240 at Canaccord
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

BNTX BioNTech
$339.40 /

-2.11 (-0.62%)

PFE Pfizer
$43.95 /

+0.04 (+0.09%)

Hot Stocks
Immunocore publishes phase 3 data comparing tebentafusp with investigator choice » 18:05
09/22/21
09/22
18:05
09/22/21
18:05
IMCR

Immunocore

$35.88 /

-0.42 (-1.16%)

The company states:…

The company states: "Immunocore announces that data from a phase 3 randomized trial comparing tebentafusp with investigator's choice in first-line metastatic uveal melanoma has been published in The New England Journal of Medicine. The paper concluded that tebentafusp is the first systemic treatment to show a survival benefit in mUM and should become a new treatment option for this poor prognosis disease. Results from the randomized, open-label, phase 3 trial of tebentafusp vs. investigator's choice in previously untreated HLA-A*02:01-positive patients with mUM demonstrated a statistically significant and clinically meaningful improvement in overall survival as a first-line treatment in mUM. The OS Hazard Ratio in the intent-to-treat population favored tebentafusp, HR=0.51. Treatment-related adverse events were manageable and consistent with the proposed mechanism. Tebentafusp has been granted Breakthrough Therapy Designation, Fast Track designation and orphan drug designation by the FDA and Promising Innovative Medicine designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma. Immunocore's biologics license application for approval of tebentafusp for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma was recently accepted by the FDA. In addition, the European Medicine Agency's Committee for Medicinal Products for Human Use accepted Immunocore's Marketing Authorisation Application."

ShowHide Related Items >><<
IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

03/02/21 Jefferies
Immunocore initiated with a Buy at Jefferies
03/02/21 JPMorgan
Immunocore initiated with an Overweight at JPMorgan
03/02/21 Goldman Sachs
Immunocore initiated with a Neutral at Goldman Sachs
IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

  • 05
    Feb
IMCR Immunocore
$35.88 /

-0.42 (-1.16%)

Hot Stocks
Yum China and Lavazza to accelerate expansion of Lavazza cafes in China » 18:05
09/22/21
09/22
18:05
09/22/21
18:05
YUMC

Yum China

$54.43 /

+0.3 (+0.55%)

Yum China and Luigi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

09/20/21 Stifel
Starbucks price target trimmed to $130 at Stifel after Yum China disclosures
09/15/21 Macquarie
Macquarie downgrades Yum China to sell on 'bumpy' sales recovery
09/15/21 Macquarie
Yum China downgraded to Underperform from Neutral at Macquarie
07/07/21 Goldman Sachs
Yum China price target raised to $77 from $74 at Goldman Sachs
YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

YUMC Yum China
$54.43 /

+0.3 (+0.55%)

Hot Stocks
AbCellera, Everest Medicines announce multi-target collaboration » 18:02
09/22/21
09/22
18:02
09/22/21
18:02
ABCL

AbCellera

$21.34 /

+0.265 (+1.26%)

AbCellera and Everest…

AbCellera and Everest Medicines have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest. The partnership will help to expand Everest's portfolio of novel medicines across multiple indications, with the initial programs focusing on targets in oncology. The collaboration will leverage AbCellera's technology stack, including sourcing fully humanized antibodies from the Trianni Mouse, sourcing single domain antibodies from camelids, and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform. Everest will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.

ShowHide Related Items >><<
ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

06/11/21 BMO Capital
AbCellera coverage transferred at BMO Capital
03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
02/08/21 SVB Leerink
AbCellera price target raised to $52 from $45 at SVB Leerink
ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

  • 11
    Dec
ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

ABCL AbCellera
$21.34 /

+0.265 (+1.26%)

Hot Stocks
Amazon partners with Billie Eilish over limited-edition Echo Studio » 17:50
09/22/21
09/22
17:50
09/22/21
17:50
AMZN

Amazon.com

$3,380.08 /

+33.19 (+0.99%)

Amazon has teamed up with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

09/14/21 Evercore ISI
Amazon price target raised to $4,700 from $4,200 at Evercore ISI
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Amazon.com initiated with a Buy at Goldman Sachs
09/10/21 BofA
Affirm price target raised to $119 from $82 at BofA
AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

AMZN Amazon.com
$3,380.08 /

+33.19 (+0.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.